• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·INDGN.BO
Share

Indegene Limited Stocks

₹ 507.85Last Updated 11.06.2026

Issuer Rating

5/7
Performance

Average

Risk

Limited

Recommendation

Hold

Market Cap

₹ 1.32B

₹ 507.85
Key Takeaways

Risk factor

Poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Indegene Limited operates as a global commercialization partner within the life sciences sector. The company assists biopharmaceutical, nascent biotechnology, and medical device organizations throughout their product's journey, from initial development and market introduction to sustained growth and impact. Its comprehensive offerings include a range of enterprise solutions for commercial, medical, and clinical operations, advanced omnichannel activation strategies, and its proprietary NEXT technology platforms. Established in 1998, the company maintains its headquarters in Bengaluru, India.

Company Valuation

Slightly overvalued
3/7

From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of fair

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of INDGN.BO is 613 and suggests 18% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

12.06.2026 01:34

Rally ahead of SpaceX debut: best day since April for S&P 500 and Nasdaq, oil down 5%

12.06.2026 01:01

SpaceX holds record IPO: Elon Musk's space company raises $75 billion

12.06.2026 00:55

Google discusses producing part of its new AI chip at Samsung factories. Is this a threat to TSMC?

12.06.2026 00:10

BofA raised its rating on Intel stock by two notches at once. What is the bank betting on?

11.06.2026 22:46

Trump canceled planned new strikes on Iran. Oil below $90 per barrel

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026